IZRL - ETF AI Analysis

Top Page

ARK Israel Innovative Technology ETF (IZRL)

Rating:55Neutral

Price Target:―

The ARK Israel Innovative Technology ETF (IZRL) has a balanced overall rating, reflecting both strengths and challenges within its portfolio. Strong contributors include Magic (MGIC), which benefits from robust growth in cloud and AI services, and JFrog (FROG), which shows strong financial performance and strategic initiatives in AI and cloud. However, weaker holdings like Nano-X Imaging (NNOX), with significant profitability and cash flow challenges, and Urogen Pharma (URGN), hindered by weak financial performance, weigh on the fund's rating. A key risk factor is the ETF's exposure to companies with valuation concerns and financial instability, which could impact long-term performance.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid gains so far this year, reflecting positive momentum.

Technology Sector Focus

Nearly half of the fund is allocated to technology, a sector known for innovation and growth potential.

Reasonable Expense Ratio

The ETF charges a moderate fee, making it cost-effective compared to actively managed funds.

Negative Factors

Underperforming Holdings

Several top holdings, such as Monday.com and Nano-X Imaging, have struggled this year, which could drag on overall returns.

Geographic Concentration

The fund is heavily weighted toward U.S. and Israeli companies, limiting exposure to other global markets.

Sector Overweight Risk

With nearly 50% of assets in technology, the ETF is vulnerable to downturns in this single sector.

IZRL vs. SPDR S&P 500 ETF (SPY)

AUM133.33M

RegionMiddle East & Africa

Expense Ratio0.49%

Beta0.83

IssuerARK

Inception DateDec 05, 2017

Dividend Yield0.33%

Asset ClassEquity

Index TrackedARK Israeli Innovation (USD)(TR)

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume15,355

30 Day Avg. Volume19,321

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IZRL Summary

The ARK Israel Innovative Technology ETF (Ticker: IZRL) is an investment fund focused on Israeli companies leading the way in technology and innovation. It includes businesses in fields like cybersecurity, artificial intelligence, and biotechnology. Some well-known companies in the ETF are Monday.com and NICE, which are recognized for their contributions to software and tech solutions. Investors might consider IZRL for its potential to grow alongside Israel's thriving tech sector and to diversify their portfolio with cutting-edge industries. However, new investors should be aware that the ETF’s performance can be heavily influenced by the ups and downs of the technology sector.

How much will it cost me?The ARK Israel Innovative Technology ETF (IZRL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 you invest. This expense ratio is slightly higher than average because the fund is actively managed and focuses on a specific niche, requiring more research and management effort.

What would affect this ETF?The ARK Israel Innovative Technology ETF (IZRL) could benefit from global demand for advanced technologies like artificial intelligence and cybersecurity, areas where Israeli companies excel. However, geopolitical tensions in the Middle East or regulatory changes affecting tech companies could pose risks to its performance. Economic conditions, such as interest rate hikes, may also impact growth-focused sectors like technology.

IZRL Top 10 Holdings

The ARK Israel Innovative Technology ETF (IZRL) is heavily tilted toward Israel’s thriving tech sector, with nearly half of its portfolio in technology stocks. Companies like Qualitau and Magic are rising stars, benefiting from robust financial performance and steady revenue growth, while JFrog shows promise despite profitability challenges. On the healthcare front, Urogen Pharma is lagging, weighed down by operational hurdles. Overall, the fund’s focus on innovation-driven industries like AI and cybersecurity positions it for long-term growth, but its concentration in tech means performance could be volatile depending on sector trends.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
TSEM	Tower	2.52%	$3.38M	43.68B	131.35%	―
TEVA	Teva Pharmaceutical	2.49%	$3.34M	$36.22B	40.68%	63 Neutral
FROG	JFrog	2.21%	$2.96M	$7.90B	118.63%	73 Outperform
TBLA	Taboola.com	2.19%	$2.94M	$1.25B	8.05%	72 Outperform
URGN	Urogen Pharma	2.15%	$2.89M	$1.11B	116.27%	50 Neutral
MGIC	Magic	2.03%	$2.72M	$1.33B	128.23%	73 Outperform
QLTU	Qualitau	2.00%	$2.68M	2.77B	182.49%	75 Outperform
ISRO	Isrotel	1.98%	$2.65M	9.30B	90.20%	71 Outperform
MTRX	Matrix	1.87%	$2.51M	9.16B	77.39%	66 Neutral
PTNR	Partner	1.87%	$2.51M	7.14B	76.42%	72 Outperform

IZRL Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

29.25

Positive

100DMA

28.64

Positive

200DMA

26.49

Positive

Market Momentum

MACD

0.36

Negative

RSI

65.42

Neutral

STOCH

86.02

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IZRL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.84, equal to the 50-day MA of 29.25, and equal to the 200-day MA of 26.49, indicating a bullish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 65.42 is Neutral, neither overbought nor oversold. The STOCH value of 86.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IZRL.

IZRL Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IZRL	―	―	$133.33M	0.49%	―
TECB	―	―	$444.40M	0.30%	―
FDTX	―	―	$196.35M	0.50%	―
LOUP	―	―	$159.74M	0.70%	―
CRTC	―	―	$113.28M	0.35%	―
ITEQ	―	―	$103.81M	0.75%	―

Performance Comparison

IZRL

ARK Israel Innovative Technology ETF

30.82

8.64

38.95%

TECB

iShares U.S. Tech Breakthrough Multisector ETF

―

FDTX

Fidelity Disruptive Technology ETF

―

LOUP

Innovator Loup Frontier Tech ETF

―

CRTC

Xtrackers US National Critical Technologies ETF

―

ITEQ

BlueStar Israel Technology ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents